GERN (29) IRWD (63) ZVRA (37) CRMD (62) ⌘ Pro Terminal →

Nuvectis Pharma Inc. (NVCT) — RQD Stock Rating Cockpit

$18.48 -0.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.43

Nuvectis Pharma Inc. (NVCT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $605.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVCT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NVCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $18.48 (-0.48% 1D, market cap $605.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCT ranks #607 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NVCT compare to GERN and IRWD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GERN (Geron Corporation) holds a E grade (29/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C grade (63/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVCT?

▼

Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $0 in revenue, -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.43 (-0.28%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVCT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY NVCT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$19.69-3.8% Next Q

Q2 (-2Q)

Grade D$18.94-2.4% Next Q

Q3 (-1Q)

Grade D$18.49-0.1% Next Q

Current

Grade D-$18.48-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NVCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NVCT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.35) and Max Pain ($19.40) forces dealer call-delta covering toward $30.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NVCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE55% OF RANGE

L: $6$18.48H: $29

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NVCT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -2.64% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (33)

10/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like NVCT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCT)

✓Walkthrough of NVCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NVCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +107.87%🛡️ HOLDING TREND SUPPORT

2026-11-02O $18.36H $18.57L $18.36C $18.48VOL 117.7K

RES: $20.88SUP: $17.67SMA50: $21.35SMA200: $14.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVCT Butterfly Map → + Track NVCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NVCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NVCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCT)

Health Care Rank #607 of 1016 ⚔️ GERN vs NVCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NVCT vs. GERN, IRWD, ZVRA, CRMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuvectis Pharma Inc. (NVCT) ranks #607 by composite RQD confidence (37/100, grade D-) and #419 by equity capitalization ($605.6M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with NVCT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NVCT ACTIVE Nuvectis Pharma Inc.	D-	37/100	—	—	-35.0%	-0.48%	$605.6M	Benchmark Subject
GERN Geron Corporation	E	29/100	—	—	-20.2%	-5.47%	$607.9M	/gern-vs-nvct →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C	63/100	24.9x	—	85.0%	-3.31%	$598.2M	/irwd-vs-nvct →
ZVRA Zevra Therapeutics Inc.	D-	37/100	7.4x	—	-32.3%	-0.77%	$615.2M	/zvra-vs-nvct →
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-25.46%	$595.5M	/crmd-vs-nvct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001875558

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvectis Pharma Inc. (NVCT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.4M, operating cash flow of -$16.0M, and free cash flow of -$16.0M (-30.7% YoY). On the balance sheet, NVCT closed FY2025 with $31.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.4M	-$16.0M	-$16.0M	$31.7M	—
FY2024 (FY)	2024-12-31	$0	-$19.0M	-$12.2M	-$12.2M	$18.6M	—
FY2023 (FY)	2023-12-31	$0	-$22.3M	-$16.0M	-$16.0M	—	—

3. NVCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NVCT compare to GERN and IRWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NVCT?

Where is NVCT trading relative to its 50-day, 200-day, and 52-week technical levels?

NVCT last traded at $18.48 (-0.48% on volume of 168,921 shares), positioning the stock -13.44% below its 50-day simple moving average ($21.35) and +26.06% above its 200-day simple moving average ($14.66). Across its 52-week range of $5.55 to $29.27, NVCT sits at the 54.5% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.17 to $20.79).

NVCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NVCT stock right now?

Nuvectis Pharma Inc. (NVCT) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is NVCT's 12-month price target and RQD AI Jury consensus?

NVCT's 12-month base price target is $16.73 (range $13.05 to $30.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NVCT RQD Cockpit NVCT 12M Forecast NVCT Earnings & Move NVCT Dividends & DRIP NVCT Insiders & 13F NVCT Whale Options NVCT Profit Sankey NVCT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NVCT — Nuvectis Pharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:34Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NVCT scores 37 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and FCF yield of -2.64%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or positive free cash flow, so the equity thesis depends on future capital access rather than current cash generation.
Whale 13F Flow: 7 / 20. The rating references institutional accumulation and options positioning, but the holders section contains no 13F detail, so the underlying positioning cannot be verified from the source data here.
Insider Conviction: 3 / 20. The lowest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow. Weak insider conviction is a caution signal because management and insiders are not showing clear buying support at current levels.
Macro Regime Fit: 10 / 20. The rating cites a beta of 1.0 and sector sensitivity. This means the stock is expected to move roughly in line with the market, with no defensive cushion from its profile.
Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2 out of 9, and Debt/Equity of 0.5. The weak Piotroski reading and the cash-burn profile point to a fragile balance sheet that may require future financing.

Taken together, the score suggests that upside depends on clinical and catalyst execution rather than on current financial strength. Valuation tradeoffs are significant: with an FCF yield of -2.64% and no reported earnings per share, traditional earnings-based valuation is not available, so price reflects expectations about pipeline outcomes. Investors evaluating the stock today face a high-dispersion outcome set, where positive trial news could move shares sharply while financing dilution or failed data could weigh heavily. This is an analytical framing, not personalized financial advice.

Open Questions

What is the company's revenue model, and is there any path to commercial product revenue given zero reported revenue across the listed periods?
What is the current debt balance, given that debt is reported as N/A in each period, and what are the financing needs implied by the FY 2025 operating loss of $-27.6M?
What is the cash runway at the FY 2025 burn rate, and are there disclosed financing or dilution arrangements?
What is the full pipeline and regulatory timeline beyond the NXP200 Phase 1b data reported in the news feed?
What are the 13F institutional holder details and insider transaction records underlying the whale and insider pillar scores?

NVCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nuvectis Pharma Inc. (NVCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NVCT Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 6h ago

NVCT: Nuvectis Pharma Inc Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 9h ago

Nuvectis Pharma, Inc. Estimates – NASDAQ:NVCT

TradingView report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing News Network • 12h ago

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Investing News Network report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 15h ago

Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas

Yahoo Finance report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18h ago

Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVC

Benzinga report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

At 12 months, survival was 95% among 20 high-grade and 100% among 7 low-grade glioma patients.

Stock Titan report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Wall Street Analysts Think Nvidia (NVDA) Could Surge 36.64%: Read This Before Placing a Bet

Yahoo Finance report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Trading Systems Reacting to (NVCT) Volatility

Stock Traders Daily report covering Nuvectis Pharma Inc. (NVCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVCT Bull vs. Bear Conversation Board — What's Your Call at $18.48?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVCT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $16.34 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NVCT (D- • RQD 37/100) a Buy at $18.57?

Welcome to the NVCT (Nuvectis Pharma Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $14.11 (-24.0%)

Spot @ $18.57

Pump the brakes on NVCT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NVCT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Nuvectis Pharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $21.73 (+17.0%)

Spot @ $18.57

NVCT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NVCT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $18.57 (52-wk range $5.55 - $29.27), any beat on forward guidance forces shorts and underweight funds to chase.